Arcus Biosciences, Inc.

NYSE:RCUS Rapporto sulle azioni

Cap. di mercato: US$1.6b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Arcus Biosciences Gestione

Gestione criteri di controllo 2/4

Arcus Biosciences' Il CEO è Terry Rosen, nominato in May2015, e ha un mandato di 9.25 anni. la retribuzione annua totale è $ 10.12M, composta da 6.4% di stipendio e 93.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 4.08% delle azioni della società, per un valore di $ 58.21M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4 anni e 4.5 anni.

Informazioni chiave

Terry Rosen

Amministratore delegato

US$10.1m

Compenso totale

Percentuale dello stipendio del CEO6.4%
Mandato del CEO9.3yrs
Proprietà del CEO4.1%
Durata media del management4.1yrs
Durata media del Consiglio di amministrazione4.5yrs

Aggiornamenti recenti sulla gestione

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

May 12
Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Terry Rosen rispetto agli utili di Arcus Biosciences?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$249m

Mar 31 2024n/an/a

-US$231m

Dec 31 2023US$10mUS$650k

-US$307m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$287m

Mar 31 2023n/an/a

-US$279m

Dec 31 2022US$9mUS$350k

-US$267m

Sep 30 2022n/an/a

US$80m

Jun 30 2022n/an/a

US$67m

Mar 31 2022n/an/a

US$58m

Dec 31 2021US$9mUS$367k

US$53m

Sep 30 2021n/an/a

-US$278m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$168m

Dec 31 2020US$6mUS$326k

-US$123m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$112m

Mar 31 2020n/an/a

-US$95m

Dec 31 2019US$2mUS$340k

-US$85m

Sep 30 2019n/an/a

-US$80m

Jun 30 2019n/an/a

-US$69m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$1mUS$295k

-US$50m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

-US$63m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$427kUS$315k

-US$53m

Compensazione vs Mercato: La retribuzione totale di Terry ($USD 10.12M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.62M ).

Compensazione vs guadagni: La retribuzione di Terry è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

Terry Rosen (64 yo)

9.3yrs

Mandato

US$10,120,945

Compensazione

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Terry Rosen
Co-Founder9.3yrsUS$10.12m4.08%
$ 67.0m
Juan Jaen
Co- Founder & President9.3yrsUS$4.75m1.56%
$ 25.6m
Robert Goeltz
Principal Financial Officer & CFO4.1yrsUS$3.59m0.017%
$ 277.5k
Jennifer Jarrett
Chief Operating Officer3.9yrsUS$4.74m0.069%
$ 1.1m
Dimitry Nuyten
Chief Medical Officer2.1yrsUS$3.69m0.015%
$ 248.1k
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno dataNessun datoNessun dato
Alexander Azoy
VP of Finance & Principal Accounting Officer1.5yrsNessun dato0.0032%
$ 53.0k
Jonathan Yingling
Chief Scientific Officer3.7yrsNessun datoNessun dato
Carolyn Tang
General Counsel & Corporate Secretary6.1yrsUS$2.92m0.052%
$ 859.9k
Holli Kolkey
Vice President of Corporate Communicationsno dataNessun datoNessun dato
Yvonne Gehring
Senior Vice President of Human Resources & Operationsno dataNessun datoNessun dato
Eric Matthews
Chief Commercial Officer5.3yrsNessun datoNessun dato

4.1yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di RCUS è considerato esperto (durata media dell'incarico 4 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Terry Rosen
Co-Founder9.4yrsUS$10.12m4.08%
$ 67.0m
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno dataNessun datoNessun dato
Yasunori Kaneko
Lead Independent Director9.3yrsUS$503.21k0.16%
$ 2.6m
Kathryn Falberg
Independent Director7yrsUS$479.08k0.16%
$ 2.7m
Andrew Perlman
Independent Director3.8yrsUS$455.83k0.023%
$ 375.7k
Jeffrey Bluestone
Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
C. Machado
Independent Director4.8yrsUS$455.83k0.018%
$ 303.3k
David Lacey
Independent Director & Member of Scientific Advisory Board4.3yrsUS$500.83k0.054%
$ 884.1k
Antoni Ribas
Independent Director & Member of Scientific Advisory Board9.7yrsUS$470.83k0.033%
$ 547.5k
Merdad Parsey
Director4.2yrsNessun datoNessun dato
Nicole Lambert
Independent Director3.1yrsUS$450.83k0.015%
$ 251.9k
Stefani Spranger
Member of Scientific Advisory Board4yrsNessun datoNessun dato

4.5yrs

Durata media

63.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RCUS sono considerati esperti (durata media dell'incarico 4.5 anni).